Association of clinicopathological and treatment characteristics with DoR ≥50% by means of univariable and multivariable logistic regression analyses
| Characteristics | DoR <50% N (%) N=65 | DoR ≥50% N (%) N=67 | Univariable analysis | Multivariable model | ||
| OR (95% CI) | P value* | OR (95% CI) | P value* | |||
| Sex | ||||||
| Female (n=63) | 27 (41.5) | 36 (53.7) | Ref | 0.162 | ||
| Male (n=69) | 38 (58.5) | 31 (46.3) | 0.61 (0.31 to 1.22) | |||
| Age (years) | ||||||
| <70 (N=92) | 51 (78.5) | 41 (61.2) | Ref | 0.033 | Ref | 0.041 |
| ≥70 (N=40) | 14 (21.5) | 26 (38.8) | 2.31 (1.07 to 4.98) | 2.46 (1.04 to 5.85) | ||
| ECOG PS | ||||||
| 0 (N=90) | 43 (66.2) | 47 (70.1) | Ref | 0.622 | ||
| ≥1 (N=42) | 22 (33.8) | 20 (29.9) | 0.83 (0.40 to 1.73) | |||
| Primary tumor sidedness | ||||||
| Left (N=34) | 18 (27.7) | 16 (23.9) | Ref | 0.617 | ||
| Right (N=98) | 47 (72.3) | 51 (76.1) | 1.22 (0.56 to 2.67) | |||
| RAS and BRAF mutational status | ||||||
| All wild-type (N=50) | 24 (36.9) | 26 (38.8) | Ref | 0.402 | ||
| RAS mutated (N=38) | 22 (33.9) | 16 (23.9) | 0.67 (0.29 to 1.57) | |||
| BRAF mutated (N=44) | 19 (29.2) | 25 (37.3) | 1.21 (0.54 to 2.74) | |||
| Synchronous metastases | ||||||
| No (N=61) | 33 (50.8) | 28 (41.8) | Ref | 0.302 | ||
| Yes (N=71) | 32 (49.2) | 39 (58.2) | 1.44 (0.72 to 2.86) | |||
| Liver metastases | ||||||
| No (N=84) | 44 (67.7) | 40 (59.7) | Ref | 0.341 | ||
| Yes (N=48) | 21 (32.3) | 27 (40.3) | 1.41 (0.69 to 2.89) | |||
| Lung metastases | ||||||
| No (N=102) | 46 (70.8) | 56 (83.6) | Ref | 0.082 | ||
| Yes (N=30) | 19 (29.2) | 11 (16.4) | 0.48 (0.21 to 1.10) | |||
| Lymph nodal metastases | ||||||
| No (N=42) | 26 (40.0) | 16 (23.9) | Ref | 0.049 | Ref | 0.009 |
| Yes (N=90) | 39 (60.0) | 51 (76.1) | 2.13 (1.01 to 4.50) | 3.15 (1.33 to 7.44) | ||
| Peritoneal metastases | ||||||
| No (N=87) | 43 (66.2) | 44 (65.7) | Ref | 0.953 | ||
| Yes (N=45) | 22 (33.8) | 23 (34.3) | 1.02 (0.50 to 2.10) | |||
| Bone metastases | ||||||
| No (N=126) | 62 (95.4) | 64 (95.5) | Ref | 0.970 | ||
| Yes (N=6) | 3 (4.6) | 3 (4.5) | 0.97 (0.19 to 4.98) | |||
| No of metastatic sites | ||||||
| 1 (N=56) | 27 (41.5) | 29 (43.3) | Ref | 0.839 | ||
| ≥2 (N=76) | 38 (58.5) | 38 (56.7) | 0.93 (0.47 to 1.86) | |||
| Prior systemic treatment for metastatic disease | ||||||
| No (N=33) | 13 (20.0) | 20 (29.9) | Ref | 0.194 | ||
| Yes (N=99) | 52 (80.0) | 47 (70.1) | 0.59 (0.26 to 1.31) | |||
| Time from metastatic condition to ICI treatment start | ||||||
| <18 months (N=91) | 38 (58.5) | 53 (79.1) | Ref | 0.012 | Ref | 0.001 |
| ≥18 months (N=41) | 27 (41.5) | 14 (20.9) | 0.37 (0.17 to 0.80) | 0.24 (0.10 to 0.57) | ||
| ICI regimen | ||||||
| Anti-PD-1 (N=84) | 49 (75.4) | 35 (52.2) | Ref | 0.006 | Ref | 0.005 |
| Anti-CTLA-4+ anti-PD-1 (N=48) | 16 (24.6) | 32 (47.8) | 2.80 (1.34 to 5.87) | 3.24 (1.42 to 7.37) | ||
*Bold values denote statistical significance.
ICI, immune checkpoint inhibitor.